Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 9
Submit an article Journal homepage
164
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Asparaginase activity monitoring experience from the Maritimes, Canada

Meghan PikeDepartment of Pediatrics, Dalhousie University/IWK Health Centre, Halifax, Nova Scotia, Canada;
,
Ketan KulkarniDepartment of Pediatrics/Division of Pediatric Hematology-Oncology, Dalhousie University/IWK Health Centre, Halifax, Nova Scotia, Canada;
&
Tamara MacDonaldDepartment of Pharmacy, Faculty of Health Professions, Dalhousie University/IWK Health Centre, Halifax, Nova Scotia, CanadaCorrespondence[email protected]
Pages 2312-2315 | Received 03 Aug 2018, Accepted 07 Jan 2019, Published online: 05 Feb 2019

References

  • Ho DH, Whitecar JP Jr, Luce JK, et al. L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow. Cancer Res. 1970;30:466–472.
  • Bleyer A, Asselin BL, Koontz SE, et al. Clinical application of asparaginase activity levels following treatment with pegaspargase. Pediatr Blood Cancer. 2015;62:1102–1105.
  • Tong WH, Pieters R, Kaspers GJL, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123:2026–2033.
  • Kumar S, Travers CD, Bergsagel J, et al. Absence of silent inactivation using intravenous pegaspargase in pediatric acute lymphoblastic leukemia. Blood. 2017;130:100.
  • Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study – Dana–Farber cancer institute ALL consortium protocol 00-01. J Clin Oncol. 2013;31:1202–1210.
  • Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of child- hood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43:5601–5607.
  • Salzer W, Bostrom B, Messinger Y, et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59:1797–1806.
  • Laboratory Instruction Manual: Assay of Clinical Samples for L-Asparaginase Levels. Version 101917. Chester (VA): NEXT Molecular Analytics©; 2015.
  • Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamics and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22:1665–1679.
  • Hempel G, Muller H, Lanvers-Kaminsky C, et al. A population pharmacokinetic model for pegylated-asparaginase in children. Br J Haematol. 2010;148:119–125.
  • Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015;56:2273–2280.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.